CRF and urocortin peptides have direct peripheral anti-inflammatory and pro-inflammatory effects through CRF receptors on immune and tissue cells, with therapeutic potential for inflammatory bowel disease, arthritis, and skin inflammation.
Key findingCRF family peptides (CRF, urocortin 1-3) modulate peripheral inflammation through CRF1 (generally pro-inflammatory) and CRF2 (generally anti-inflammat
What the researchers found
CRF family peptides (CRF, urocortin 1-3) modulate peripheral inflammation through CRF1 (generally pro-inflammatory) and CRF2 (generally anti-inflammatory) receptors on immune cells, gut, and skin — with therapeutic applications for IBD, arthritis, and dermatitis.
Why it matters
Relevant for neuropeptides, inflammation, anxiety-mood, receptor-signaling.
How the study worked
review study on neuropeptides, inflammation.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications.
Current medicinal chemistry, 12(13), 1503-12
Citation
Gravanis, Achille; Margioris, Andrew N. (2005). The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications.. Current medicinal chemistry, 12(13), 1503-12.